Evidence mapPaperPMID 41459550Full record

ArticleBio-protocol2025

An Ex Vivo Lung Histoculture Model for Studying Pulmonary Infection and Immune Response With SARS-CoV-2 as an Example of RNA Virus.

Elena V Maryukhnich, Daria M Potashnikova, Daria A Vorobyeva, George I Rusakovich, Anna V Tvorogova, Anna I Kalinskaya, Natalia V Pinegina, Anna V Kovyrshina, Inna V Dolzhikova, Alexander B Postnikov and 6 more

Abstract read
In one paragraph

Article in Bio-protocol, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elena V MaryukhnichLaboratory of Atherothrombosis, Cardiology Department, Federal State Budgetary Educational Institution of Higher Education (FSBEI HE) "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Daria M PotashnikovaLaboratory of Atherothrombosis, Cardiology Department, Federal State Budgetary Educational Institution of Higher Education (FSBEI HE) "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Daria A VorobyevaLaboratory of Atherothrombosis, Cardiology Department, Federal State Budgetary Educational Institution of Higher Education (FSBEI HE) "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia.
George I RusakovichI.V. Davydovsky Moscow City Clinical Hospital, Moscow Department of Healthcare, Moscow, Russia.
Anna V TvorogovaI.V. Davydovsky Moscow City Clinical Hospital, Moscow Department of Healthcare, Moscow, Russia.
Anna I KalinskayaLaboratory of Atherothrombosis, Cardiology Department, Federal State Budgetary Educational Institution of Higher Education (FSBEI HE) "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Natalia V PineginaLaboratory of Atherothrombosis, Cardiology Department, Federal State Budgetary Educational Institution of Higher Education (FSBEI HE) "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Anna V KovyrshinaFederal Government Budgetary Institution "The National Research Center for Epidemiology and Microbiology Named After Honorary Academician N.F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Inna V DolzhikovaFederal Government Budgetary Institution "The National Research Center for Epidemiology and Microbiology Named After Honorary Academician N.F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Alexander B PostnikovHyTest Ltd, Turku, Finland.
Fedor N RozovHyTest Ltd, Turku, Finland.
Tatiana N SotnikovaI.V. Davydovsky Moscow City Clinical Hospital, Moscow Department of Healthcare, Moscow, Russia.
Dmitry Yu KannerMoscow City Oncology Hospital No 62, Moscow, Russia.
Denis Yu LogunovFederal Government Budgetary Institution "The National Research Center for Epidemiology and Microbiology Named After Honorary Academician N.F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Alexander L GintsburgFederal Government Budgetary Institution "The National Research Center for Epidemiology and Microbiology Named After Honorary Academician N.F. Gamaleya" of the Ministry of Health of the Russian Federation, Moscow, Russia.
Elena J VasilievaLaboratory of Atherothrombosis, Cardiology Department, Federal State Budgetary Educational Institution of Higher Education (FSBEI HE) "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tissue explant culture (histoculture) is a method that involves maintaining small pieces taken from an organ ex vivo or post mortem in a controlled laboratory setting. Such a technique has a number of advantages: unlike the 2D, organoid, or on-chip cultures, tissue explants preserve the whole complexity of the original tissue in vivo, its structure, extracellular matrix, and the diverse cell populations, including resident immune cells. The explant culture method can be applied to human tissue specimens obtained from biopsies or autopsies, provided that proper ethical protocols are followed. This avoids the difficulties that may arise in translating results obtained on animal models into biomedical research for humans. This advantage makes histocultures especially desirable for studying human pathogenesis in the course of infectious diseases. The disadvantage of the method is the limited lifespan of the cultured tissues; however, a number of approaches allow extending tissue viability to a period sufficient for observing the infection onset and development. Here, we provide a protocol for lung explant maintenance that allows tracing the local effects of infection with SARS-CoV-2 in humans. Further applications of the lung tissues cultured according to this protocol include, but are not limited to, histochemical and immunohistochemical studies and microscopy, FACS, qPCR, and ELISA-based analysis of the conditioned culture media. Key features • The protocol relies on lung tissue culture on collagen rafts at the air-liquid interface, followed by infection with viral agents. • The developed system provides a laboratory-controlled model to investigate the mechanisms of SARS-CoV-2 infection and allows further histological/immunohistochemical, qPCR, FACS, and xMAP cytokine analysis. • Successful establishment of explant culture requires basic cell culture experience. Successful viral infection requires access to a BSL3 laboratory and relevantly trained personnel.

Indexed as

Antiviral responseCOVID-19CytokinesEx vivo modelImmune responseLung explant ex vivo cultureSARS-CoV-2

Identifiers

PMID41459550
PMCPMC12739473

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.